There are currently 70 clinical trials in Arlington, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Clinical Research Institute, Texas Clinical Research Institute LLC, Texas Retina Associates and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Arlington Aging Study
NCT06857877
Recruiting
The goal of this observational study is to learn about the mechanisms causing functional decline with age, using exercise science, neuroscience, and remote monitoring. Specific aims include: Aim 1: Advance knowledge of the biology of aging and its impact on the prevention, progression, and prognosis of disease and disability. Aim 2: Determine the effects of personal and societal factors on aging. Aim 3: Examine the influence of racial/ethnic and sex differences on the biology of aging and it... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/27/2025
Locations: University of Texas Arlington, Arlington, Texas
Conditions: Aging
Register for Updates
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
NCT06538116
Recruiting
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
02/26/2025
Locations: Cedar Health Research LLC, Arlington, Texas
Conditions: Alzheimer Disease
Register for Updates
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Site 110, Arlington, Texas
Conditions: Advanced Solid Tumor
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: The Center for Cancer & Blood Disorders - Magnolia,515 W. Mayfield Rd., Arlington, Texas
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
NCT06843239
Recruiting
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/20/2025
Locations: Rheumatology Associates, Arlington, Texas
Conditions: Systemic Sclerosis (SSc), Scleroderma
Register for Updates
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with Moderate to Severe Hidradenitis Suppurativa
NCT06603077
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Clinical site 1012, Arlington, Texas
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06571045
Recruiting
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Arlington, TX, Arlington, Texas
Conditions: Diabetic Macular Edema (DME)
Register for Updates
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376
Recruiting
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Research Site, Arlington, Texas
Conditions: Immunoglobulin A Nephropathy, IgAN
Register for Updates
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235
Recruiting
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Urology Associates of North Texas, Arlington, Texas
Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Register for Updates
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
NCT04123795
Recruiting
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
01/23/2025
Locations: Ps0007 50156, Arlington, Texas
Conditions: Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
Register for Updates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918
Recruiting
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration
Gender:
ALL
Ages:
50 years and above
Trial Updated:
01/10/2025
Locations: Texas Retina Associates, Arlington, Texas
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults with Depression
NCT05966532
Recruiting
This is a cross-sectional pilot study designed to establish hot and cold cognitive functions and underlying neurocircuitry in older adults with MDD. The investigators will study 120 participants aged 21-80 years old with MDD. All participants will undergo clinical and neurocognitive assessment, and Magnetoencephalography (MEG)/Magnetic resonance imaging (MRI) procedures at one time point. The investigators will also enroll 120 demographically matched comparable, never-depressed healthy participa... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
01/08/2025
Locations: University of Texas Arlington, Arlington, Texas
Conditions: Major Depressive Disorder (MDD), Healthy Adult Volunteer
Register for Updates